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The reports pertaining to the mitigation and treatment of the COVID-19 pandemic are still lacking. Compatibility of the 
natural products and availability of the modern computational techniques motivated us to carry out In Silico investigations 
on some bioactive natural compounds reportedly found in the fruits and leaves of Anthocephalus Cadamba commonly 
known as Kadam or Kadamb Tree, aiming to predict the potential inhibitors against the aforesaid virus. Having modeled the 
ground state ligand structure of the nine natural compounds applying density functional theory at B3LYP/631+G (d, p) 
level, we have performed their molecular docking with SARS-COV-2 protease to calculate the binding affinity as well as to 
screen the binding at S-protein site during ligand-protein interactions. Out of these nine studied naturally occurring 
compounds; Oleanic Acid has been appeared to be a potential inhibitor for COVID-19 followed by Ursolic Acid, 
Iso-Vallesiachotamine, Vallesiachotamine, Cadambine, Vincosamide-N-Oxide, Isodihydroamino-cadambine, Pentyle Ester 
of Chlorogenic Acid and D-Myo-Inositol. Hence, these bioactive natural compounds or their structural analogs may be 
explored as an anti-COVID-19 drug agents. The solubility and solvent-effect related to the phytochemicals may be the point 
of concern. In vivo investigations on these proposed natural compounds or their structural analogs are invited for designing 
and developing the potential medicine/vaccine for the treatment of COVID-19 pandemic. 
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The severe acute respiratory syndrome coronavirus 
(SARS-COV-2) identified as COVID-19 in Wuhan 
City of China
1
 spread across the earth as pandemic 
putting the whole world on high alert
2–5
 led to 823626 
total cases and 40598 deaths all over the world till 01 
April 2020
6
. Available evidence indicates that this 
virus is transmitted through the respiratory droplets 
(such as coughing) and by fomites that can propagate 
through the air at distances of 1 M
7,8
 and no evidence 
is available about its airborne transmission in the 
current study
9
 which establishes the principle of 
maintaining the distance of more than 1 meter termed 
as ‘social distancing’/physical distancing’ along with 
hand-hygiene for the prevention of COVID-19. A 
recent study based on the mathematical modeling 
conducted by the Indian Council of Medical Research 
(ICMR) has suggested the proper quarantine and 
isolation as the preventive measures for stopping the 
outbreak of COVID-19 through community 
transmission
10
. It appears that in view of this, country- 
wide lock-down has been declared in India since the 
midnight of the 23
rd
 March 2020 in continuation to 
pre-lock down the action of evacuating the possible 
places expected for people’s gathering as well as the 
social awareness drive already started from the very 
beginning of February, 2020 which we welcome. 
Appreciable contribution in the development of 
diagnostics, therapeutics, and vaccines for this novel 
coronavirus has been indicated
11
, and based on some 
clinical investigations, an anti-malarial drug namely 
chloroquine phosphate has been reported to be having 
a certain curative effect on the COVID-19
12
. ICMR 
has also recommended an anti-malarial drug namely 
Hydroxy-chloroquine for those individuals who are 
asymptomatic healthcare workers involved in the care 
of suspected or confirmed cases of COVID-19 and 
asymptomatic household contacts of laboratory- 
confirmed cases
13
. The possibility of high risk-factor 
associated with these suggested drugs has not been 
ruled out which projected it to be a trial measure. No 
specific therapy and medicine for the treatment of 
COVID-19 has ever been reported to the best of our 
knowledge which inspired us to think on the natural 
products relying on the concept of particle-antiparticle 
theory of Nature implying that if there is a novel 
coronavirus then there must be its anti-virus material 
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results in the present research carried out with the 
help of available computational facility at our home 
during lock-down period. 
We have selected total eleven bioactive 
natural compounds embedded spontaneously in 
Anthocephalus Cadamba which has been reported to 
be a miraculous tree having crucial significance in 
Hindu Mythology containing the largest number of 
phytochemicals and secondary metabolites having 
pharmacological and biological properties, however, 
the solubility and solvent-effect to be the point of 
concern
14
. The four bio molecules contained 
in the leaves of the said tree namely 7-hydroxy-6-
methoxy coumarian (C10H8O4), Methyl ester of 
chlorogenic acid (C17H20O9), Pentyle Ester of 
Chlorogenic Acid (C21H28O9), D-Myo-Inositol 
(C7H14O6); 07 biomolecules contained in fruits of the 
said tree namely Oleanic Acid (C30H48O3), Ursolic 
Acid (C30H48O3), Vallesiachotamine (C21H22N2O3), 
Iso-Vallesiachotamine (C21H22N2O3), Cadambine 
(C27H32N2O10), Vincosamide-N-Oxide (C26H31N2O9), 
Isodihydroamino-cadambine (C26H33N3O7) already 
reported to be isolated and characterized in Central 
Drug Research Institute, Lucknow, India
15,16
 and the 
electronic properties of the few of them have already 
been studied by us computationally
17-21
; were 
screened as ligands to interact with the targeted 
SARS-COV-2 protease. The first two of the aforsaid 
compounds responded negatively but rest nine 
compounds exhibited the positive results which have 
been presented in this paper. We expect that the 
present study will offer a new dimension in 
developing the drug/vaccine for the COVID-19.  
Methodology 
The In silico optimized ligand-structure of the 
aforementioned eleven bioactive natural compounds 
were obtained as per reported approach of density 
functional theory at B3LYP/631+G (d, p) level
22-23
 
implemented through Gaussian 09 program-
package
24
. We have used main protease of SARS-
COV-2 retrieved from the RCSB protein data bank 
having PDB ID: 6Y84
25
 and PDB ID: 6LU7
26
 as 
potential target protein for the binding of these 
compounds as ligands. The protein-ligand interaction 
has been studied by using molecular docking which 
has been observed to be compatible approach in the 
recent reports
27,28
 and we have implemented 
molecular docking theory through Autodock 4.2 
program package
29-31
.The binding of these natural 
bioactive ligands with the PDB ID: 6CRV which is 
SARS Spike Glycoprotein for coronavirus SARS-
COV emerged in 2002 as a highly transmissible
32
 has 
also been obtained with the help of same docking 
approach in order to investigate the consistency of the 
performance of these compounds with the class of 
viral protein. The binding of these compounds with 
the PDB ID: 6VXX which is the SARS-COV-2 spike 
glycoprotein for COVID-19
33
 has also been examined 
to illustrate the potential of these compounds to 
deactivate this novel coronavirus at the receptor end. 
Results 
The In silico optimized molecular structure of 09 
bioactive natural compounds modeled using DFT-
B3LY/6-31+G (d,p) level of theory which exhibited 
the property of inhibitor against the main protease of 
COVID-19, have been displayed in (Fig. 1). Binding 
affinity in each cluster rank for the complete cycle of 
ligand-proteins (PDB ID: 6Y84, 6LU7 and 6CRV) 
interactions have been depicted in (Table 1) for 
Oleanic Acid (molecule 1), for Ursolic Acid 
(molecule 2), for Iso-Vallesiachotamine (molecule 3), 
for Vallesiachotamine (molecule 4), for Cadambine 
(molecule 5), for Vincosamide-N-Oxide (molecule 6), 
for Isodihydroamino-cadambine (molecule 7), for 
Pentyle Ester of Chlorogenic Acid (molecule 8) and 
for D-Myo-Inositol (molecule 9). The significant 
binding of these natural compounds as ligand with the 
said protease results in the conformational changes in 
the target protein 6Y84, 6LU7 and 6CRV as displayed 
in (Fig. 2A) for molecule 1, (Fig. 2B) for molecule 2, 
(Fig. 2C) for molecule 3 (Fig. 2D) for molecule 4, 
(Fig. 2E) for molecule 5, (Fig. 2F) for molecule 6, 
(Fig. 2G) for molecule 7, (Fig. 2H) molecule 8 and 
(Fig. 2I) for molecule 9. 
The significantly negative value of free energy of 
binding of these molecules as a ligand with SARS-
COV-2 spike glycoprotein for COVID-19 (PDB ID: 
6VXX) in ligand-protein interaction has also been 
obtained and the results of best five have been 
presented in (Table 2).  
The significantly negative value of free energy of 
binding of these molecules with PDB ID: 6VXX 
(SARS-COV-2 spike glycoprotein for COVID-19) in 
ligand-protein interaction as depicted in (Table 2) 
have been obtained and corresponding conformational 
changes occurred in the target protein are presented in 
(Figs. 3 & 4). 
Similar types of significant binding affinity have 
been obtained in all the SARS-COV-2 spike 
glycoprotein –ligand (studied compounds) interactions  
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Fig. 1 — The optimized molecular structure of studied Bioactive Natural Compounds *reported to be found in fruits (molecule no 1 to 7) 
and leaves (molecule no 8 to 9) of Anthocephalus cadamba14-16. Blue balls: N-atoms, black balls: C-atoms, white balls: H-atoms, red 
balls: O-atoms 
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Fig. 2 — Conformational changes observed due to the binding of (A) ligand-1 (Oleanic Acid); (B) ligand-2 (Ursolic Acid); (C) ligand-3 
(Iso-Vallesiachotamine); (D) ligand-4 (Vallesiachotamine); (E) ligand-5 (Cadambine); (F) ligand-6 (Vincosamide-N-Oxide); (G) ligand-7 
(Isodihydroamino-cadambine); (H) ligand-8 (Pentyle Ester of Chlorogenic Acid); (I) ligand-9 (D-Myo-Inositol) with the COVID-19 
protease and S-protein receptor 
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Table 1 — Binding Affinity of natural compounds with the target proteins 





(PDB ID: 6Y84) 
SARS-COV-2 protease 
(PDB ID: 6LU7) 
SARS-COV Spike Glycoprotein 
(PDB ID: 6CRV) 








Free Energy of 
Binding 
Inhibition Constant 
1 −11.28 kcal/mol 5.38 nM −6.11 kcal/mol 33.45 μM −5.90 kcal/mol 47.30 μM 
2 −9.78 kcal/mol 67.90 nM −5.83 kcal/mol 52.86 μM −5.73 kcal/mol 63.60 μM 
3 −9.60 kcal/mol 91.21 nM −5.70 kcal/mol 66.07 μM −5.41 kcal/mol 107.78 μM 
4 −9.10 kcal/mol 213.24 nM −5.59 kcal/mol 79.53 μM −4.91 kcal/mol 249.99 μM 
Oleanic 5 --------- --------- −5.57 kcal/mol 82.47 μM −4.39 kcal/mol 607.04 μM 
Acid 6 --------- --------- −5.44 kcal/mol 102.54 μM −4.28 kcal/mol 723.95 μM 
(C30H48O3) 7 --------- --------- −5.08 kcal/mol 189.25 μM −4.25 kcal/mol 768.82 μM 
8 --------- --------- −4.89 kcal/mol 258.48 μM --------- --------- 
9 --------- --------- -4.77 kcal/mol 318.64 μM --------- --------- 
1 −10.94 kcal/mol 9.63 nM −6.40 kcal/mol 20.38 μM −6.96 kcal/mol 7.88 μM 
2 −10.30 kcal/mol 28.35 nM −6.34 kcal/mol 22.70 μM −6.81 kcal/mol 10.26 μM 
3 −9.74 kcal/mol 72.73 nM −6.00 kcal/mol 40.32 μM −6.76 kcal/mol 11.17 μM 
Ursolic 4 −9.72 kcal/mol 74.54 nM −5.89 kcal/mol 47.97 μM −6.61 kcal/mol 14.24 μM 
Acid 5 −9.36 kcal/mol 137.19 nM −5.34 kcal/mol 122.36 μM −6.30 kcal/mol 24.24 μM 
(C30H48O3) 6 −8.90 kcal/mol 299.83 nM −4.96 kcal/mol 232.96 μM −6.19 kcal/mol 29.17 μM 
7 --------- --------- --------- --------- −6.14 kcal/mol 31.59 μM 
8 --------- --------- --------- --------- −6.08 kcal/mol 34.90 μM 
9 --------- --------- --------- --------- −5.91 kcal/mol 46.80 μM 
10 --------- --------- --------- --------- −5.86 kcal/mol 50.93 μM 
1 −9.55 kcal/mol 99.42 nM −6.00 kcal/mol 39.82 μM −5.16 kcal/mol 165.89 μM 
2 −7.93 kcal/mol 1.53 μM −5.71 kcal/mol 65.58 μM −5.00 kcal/mol 214.52 μM 
3 −7.63 kcal/mol 2.54 μM −5.70 kcal/mol 66.53 μM −4.94 kcal/mol 237.57 μM 
4 −7.61 kcal/mol 2.63 μM −5.35 kcal/mol 20.56 μM −4.81 kcal/mol 296.22 μM 
Iso- 5 −7.45 kcal/mol 3.43 μM −5.11 kcal/mol 178.30 μM −4.75 kcal/mol 332.16 μM 
 Vallesiachotamine 6 −6.51 kcal/mol 16.94 μM −4.86 kcal/mol 275.30 μM −4.70 kcal/mol 357.55 μM 
(C21H22N2O3) 7 --------- --------- --------- --------- −4.68 kcal/mol 370.48 μM 
8 --------- --------- --------- --------- −4.45 kcal/mol 548.28 μM 
9 --------- --------- --------- --------- −4.36 kcal/mol 640.89 μM 
10 --------- --------- --------- --------- −4.03 kcal/mol 1.11 mM 
1 −9.50 kcal/mol 109.66 nM −4.98 kcal/mol 224.33 μM −6.35 kcal/mol 22.14 μM 
2 −9.32 kcal/mol 148.51 nM −4.80 kcal/mol 302.86 μM −6.04 kcal/mol 37.63 μM 
3 −8.77 kcal/mol 371.00 nM −4.43 kcal/mol 564.68 μM −5.52 kcal/mol 89.42 μM 
4 −8.33 kcal/mol 784.52 nM −4.31 kcal/mol 693.59 μM −5.05 kcal/mol 197.72 μM 
Vallesiachotamine 5 −6.91 kcal/mol 8.64 μM −4.30 kcal/mol 699.66 μM −4.88 kcal/mol 262.69 μM 
(C21H22N2O3) 6 −6.87 kcal/mol 9.28 μM −4.28 kcal/mol 723.92 μM −4.77 kcal/mol 320.94 μM 
7 −6.62 kcal/mol 13.94 μM −3.94 kcal/mol 1.30 mM −4.36 kcal/mol 633.00 μM 
8 --------- --------- −3.73 kcal/mol 1.84 mM −4.25 kcal/mol 769.77 μM 
9 --------- --------- −2.84 kcal/mol 8.22 mM −4.02 kcal/mol 1.12 mM 
10 --------- --------- --------- --------- −3.90 kcal/mol 1.39 mM 
1 −8.85 kcal/mol 323.97 nM −6.93 kcal/mol 13.86 μM −5.35 kcal/mol 118.85 μM 
2 −7.57 kcal/mol 2.81 μM −4.80 kcal/mol 301.24 μM −4.83 kcal/mol 287.35 μM 
3 −7.46 kcal/mol 3.39 μM −4.44 kcal/mol 553.34 μM −4.65 kcal/mol 391.37 μM 
4 −7.18 kcal/mol 5.45 μM −4.26 kcal/mol 756.51 μM −4.56 kcal/mol 451.55 μM 
Cadambine 5 −6.79 kcal/mol 10.57 μM −4.24 kcal/mol 779.20 μM −4.33 kcal/mol 673.01 μM 
(C27H32N2O10) 6 −6.22 kcal/mol 27.54 μM −4.05 kcal/mol 1.07 mM −4.24 kcal/mol 783.98 μM 
7 −6.15 kcal/mol 30.85 μM −4.03 kcal/mol 1.11 mM −3.78 kcal/mol 1.71 mM 
8 −5.85 kcal/mol 51.89 μM −3.72 kcal/mol 1.88 mM −3.50 kcal/mol 2.70 mM 
9 −5.72 kcal/mol 64.44 μM −3.33 kcal/mol 3.60 mM −3.06 kcal/mol 5.75 mM 
10 −5.45 kcal/mol 100.34 μM −3.31 kcal/mol 3.77 mM −2.88 kcal/mol 7.78 mM 
(Contd.) 
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Table 1 — Binding Affinity of natural compounds with the target proteins (Contd.) 





(PDB ID: 6Y84) 
SARS-COV-2 protease 
(PDB ID: 6LU7) 
SARS-COV Spike Glycoprotein 
(PDB ID: 6CRV) 












1 −8.81 kcal/mol 348.65 nM −5.81 kcal/mol 55.52 μM −4.59 kcal/mol 434.05 μM 
2 −8.77 kcal/mol 370.30 nM −4.78 kcal/mol 312.98 μM −4.47 kcal/mol 532.26 μM 
3 −8.41 kcal/mol 686.48 nM −4.49 kcal/mol 511.38 μM −4.28 kcal/mol 730.11 μM 
4 −8.08 kcal/mol 1.19 μM −3.93 kcal/mol 1.31 mM −4.05 kcal/mol 1.07 mM 
Vincosamide- 5 −7.92 kcal/mol 1.58 μM −3.89 kcal/mol 1.40 mM −4.00 kcal/mol 1.17 mM 
N-Oxide 6 −7.70 kcal/mol 2.26 μM −3.75 kcal/mol 1.79 mM −3.49 kcal/mol 2.78M 
(C26H31N2O9) 7 −7.22 kcal/mol 5.08 μM −3.48 kcal/mol 2.83 mM −3.44 kcal/mol 3.02 mM 
8 −6.26 kcal/mol 25.76 μM −3.41 kcal/mol 3.15 mM −3.38 kcal/mol 3.31 mM 
9 −5.08 kcal/mol 187.55 μM −3.33 kcal/mol 3.64 mM −3.29 kcal/mol 3.91 mM 
10 --------- --------- −3.03 kcal/mol 5.96 mM −3.04 kcal/mol 5.93 mM 
1 −8.57 kcal/mol 520.33 nM −4.85 kcal/mol 277.88 μM −4.10 kcal/mol 922.19 μM 
2 −7.88 kcal/mol 1.67 μM −4.10 kcal/mol 990.69 μM −3.90 kcal/mol 1.39 mM 
3 −6.49 kcal/mol 17.43 μM −4.08 kcal/mol 1.02 mM −3.53 kcal/mol 2.60 mM 
4 −5.27 kcal/mol 137.23 μM −3.09 kcal/mol 5.42 mM −3.44 kcal/mol 2.99 mM 
Isodihydroamino-  5 −5.11 kcal/mol 181.03 μM −2.92 kcal/mol 7.26 mM −3.31 kcal/mol 3.73 mM 
cadambine 6 −4.76 kcal/mol 324.79 μM −2.58 kcal/mol 12.88 mM −3.00 kcal/mol 6.28 mM 
(C26H33N3O7) 7 −4.21 kcal/mol 816.29 μM −2.53 kcal/mol 14.04 mM −2.97 kcal/mol 6.63 mM 
8 −3.90 kcal/mol 1.39 mM −2.51 kcal/mol 14.54 mM −2.88 kcal/mol 7.71 mM 
9 --------- --------- −1.04 kcal/mol 172.81 mM −2.84 kcal/mol 8.27 mM 
10 --------- --------- --------- --------- −2.69 kcal/mol 10.75 mM 
1 −5.61 kcal/mol 77.71 μM −1.95 kcal/mol 37.57 mM −2.35 kcal/mol 19.10 mM 
2 −5.10 kcal/mol 182.54 μM −1.52 kcal/mol 76.24 mM −1.77 kcal/mol 50.49 mM 
3 −5.06 kcal/mol 194.58 μM −1.46 kcal/mol 85.21 mM −1.66 kcal/mol 60.43 mM 
4 −5.05 kcal/mol 198.85 μM −1.03 kcal/mol 176.88 mM −1.64 kcal/mol 62.51 mM 
Chlorogenic acid  5 −4.18 kcal/mol 869.07 μM −0.86 kcal/mol 233.66 mM −1.37 kcal/mol 99.72 mM 
(C21H28O9) 6 −3.40 kcal/mol 3.21 mM −0.61 kcal/mol 356.69 mM −1.23 kcal/mol 126.32 mM 
7 −3.30 kcal/mol 3.80 mM −0.42 kcal/mol 490.95 mM −1.03 kcal/mol 176.85 mM 
8 −3.15 kcal/mol 4.87 mM −0.37 kcal/mol 531.76 mM −0.20 kcal/mol 713.11 mM 
9 −3.03 kcal/mol 6.04 mM −0.06 kcal/mol 903.01 mM −0.10 kcal/mol 840.36 mM 
10 −2.86 kcal/mol 8.01 mM +0.05 kcal/mol ------------ −0.00 kcal/mol 991.66 mM 
1 −5.51 kcal/mol 90.67 μM −2.22 kcal/mol 23.63 mM −3.11 kcal/mol 5.22 mM 
2 −5.06 kcal/mol 195.69 μM −2.05 kcal/mol 31.17 mM −2.77 kcal/mol 9.34 mM 
3 −4.30 kcal/mol 702.05 μM −1.86 kcal/mol 43.37 mM −2.64 kcal/mol 11.57 mM 
4 −3.56 kcal/mol 2.47 μM −1.74 kcal/mol 53.02 mM −2.53 kcal/mol 13.88 mM 
D-Myo-Inositol 5 −3.04 kcal/mol 5.86 mM −1.72 kcal/mol 54.66 mM −2.32 kcal/mol 20.09 mM 
(C7H14O6) 6 −3.00 kcal/mol 6.30 mM −1.53 kcal/mol 75.47 mM −2.30 kcal/mol 20.46 mM 
7 −2.93 kcal/mol 7.09 mM −1.38 kcal/mol 98.07 mM −2.11 kcal/mol 28.50 mM 
8 --------- --------- −1.10 kcal/mol 154.91 mM −1.98 kcal/mol 35.50 mM 
9 --------- --------- −1.07 kcal/mol 164.03 mM −1.94 kcal/mol 37.54 mM 
10 --------- --------- --------- --------- −1.56 kcal/mol 71.41 mM 
Table 2 — Binding affinity of a studied molecule with SARS-COV-2 spike glycoprotein 
Cluster 
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Table 2 — Binding affinity of a studied molecule with SARS-COV-2 spike glycoprotein 
Cluster 










































































































































Fig. 3 — (A) Oleanic Acid - 6VXX interaction; (B) Ursolic Acid - 6VXX interaction, & (C) Vincosamide-N-Oxid- 6VXX interaction 
Fig. 4 — (A) Iso-Vallesiachotamine - 6VXX interaction; & (B) Isodihydroamino-cadambine - 6VXX interaction 
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whose results are available on demand but not 
depicted due to space limitations. 
Discussion 
We observe the complete cycle for the binding of 
all these compounds with the said protease in 
maximum ten cluster run and the final free energy of 
binding is significant for all the ligand-protein 
interactions. The final free energy of binding and 
nucleic acid residue sites of binding which induce the 
conformational changes in the target protein and may 
result in the deactivation of the SARS-COV-2 virus 
has been presented in (Table 3).  
The significantly negative value of the final free 
energy of binding obtained through the molecular 
docking of these compounds with the SARS-COV-2 
protease and the observed nucleic acid residues sites 
of binding reveal that these molecules may be 
explored as potential inhibitor against COVID-19. 
The insignificant result for the binding of molecule 
no.8 (pentyl ester of chlorogenic acid) with 6LU7 and 
6CRV receptors have been obtained whereas the same 
molecule exhibits a significant final free energy of 
binding with 6Y84 protease of COVID-19 as obvious 
from the (Table 1). Since these compounds are 
naturally occurring, hence they do not cost for their 
synthesis and bears less or nil side-effect which 
enables them to be explored as user-friendly drug 
candidate for SARS-COV-2 virus. However, the 
solubility and the effect of the solvent which are 
usually associated with the phytochemicals may be 
the point of attention while using these compounds as 
drug candidate. The other chemical structure may also 
be derived from these bioactive natural compounds to 
further design potential drug agent for COVID-19. 
The binding of randomly selected five molecules with 
the SARS-COV-2 spike glycoprotein as depicted in 
the (Table 3), reveals that these molecules or their 
structural-derivatives may stop the replication of this 
virus at the receiver end in the human body. 
Conclusion 
We have carried out a schematic In silico 
investigation applying density functional theory and 
molecular docking approach on the nine naturally 
Table 3 — Final free energy of binding and nucleic acid residue sites in the studied ligand-protein interactions 
S No. Name of 
Ligands 











































LYS-97 −4.25 kcal/mol 
at 768.82 μM 
VAL-147 −5.45 kcal/mol 
at 101.12 μM 
ASP-428 








ASN-238 −5.86 kcal/mol 
at 50.93 μM 
ASP-850 −5.81 kcal/mol 











SER-267 −4.03 kcal/mol 


























































GLU-240 −1.04 kcal/mol 
at 172.81 mM 
ASR-330 −2.69 kcal/mol 
at 10.75 mM 
ASN-955 −2.53 kcal/mol 
at 14.00 mM 
GLY-282 
















PHE-219 −1.56 kcal/mol 
at 71.41 mM 
NA NA NA 
NA: This protease has been left in the random selection to perform Molecular docking and does not implicate that data are not available 
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occurring bioactive compounds listed in (Table 2) 
spontaneously found in the leaves and fruits of 
Anthocephalus cadamba. On the basis of the binding 
affinity, we have found these compounds as potential 
inhibitors against the COVID-19 having final free 
energy of binding in the order of molecule 
1>2>3>4>5>6>7>8>9. These compounds have emerged 
as potential inhibitors against the SARS-COV-2 
protease in our investigation; hence, an in vivo study is 
invited on these compounds for developing user-friendly 
drug for COVID-19. The pre-print of this research is 
announced by the archive of Cornell University, USA
34
. 
The further study on derived structures of these 
compounds is going on in our laboratory. Reports on 
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